drospirenone has been researched along with Obesity in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajuk Studen, K; Jensterle Sever, M; Pfeifer, M | 1 |
| Antelmi, A; Armani, A; Canese, R; Caprio, M; Carpinelli, G; Cinti, F; Cinti, S; Cranston, GA; Fabbri, A; Malorni, W; Marconi, M; Marzolla, V; Matarrese, P; Morgan, J; Pagotto, U; Quarta, C; Rosano, G; Young, MJ | 1 |
| Battaglia, C; Busacchi, P; Cianciosi, A; Facchinetti, F; Mancini, F; Persico, N | 1 |
| Casanova, GK; Ramos, RB; Spritzer, PM | 1 |
| Schwetz, BA | 1 |
1 review(s) available for drospirenone and Obesity
| Article | Year |
|---|---|
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thickness; Coronary Artery Disease; Female; Humans; Hypertension; Incretins; Insulin Resistance; Life Style; Metformin; Middle Aged; Obesity; Polycystic Ovary Syndrome; Postmenopause; Renin-Angiotensin System; Risk Factors; Sleep Apnea, Obstructive; Thiazolidinediones; Vascular Stiffness; Weight Reduction Programs | 2013 |
1 trial(s) available for drospirenone and Obesity
| Article | Year |
|---|---|
Fat mass and obesity-associated gene polymorphisms do not affect metabolic response to hormone therapy in healthy postmenopausal women.
Topics: Adult; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Androstenes; Body Composition; Body Mass Index; C-Reactive Protein; Cross-Over Studies; Estradiol; Estrogen Replacement Therapy; Female; Humans; Lipids; Middle Aged; Obesity; Polymorphism, Single Nucleotide; Postmenopause; Progesterone; Proteins; Waist Circumference | 2012 |
3 other study(ies) available for drospirenone and Obesity
| Article | Year |
|---|---|
Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Aldosterone; Androstenes; Animals; Autophagy; Body Composition; Cell Transdifferentiation; Cells, Cultured; Diet, High-Fat; Female; Gene Expression Profiling; Glucose Intolerance; Inguinal Canal; Intra-Abdominal Fat; Ion Channels; Macrolides; Mice; Mice, Inbred C57BL; Mineralocorticoid Receptor Antagonists; Mitochondrial Proteins; Obesity; Receptors, Mineralocorticoid; Spironolactone; Uncoupling Protein 1; Up-Regulation; Weight Gain | 2014 |
Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study.
Topics: Adolescent; Adult; Androstenes; Brachial Artery; Cardiovascular Diseases; Contraceptives, Oral; Endothelin-1; Female; Homocysteine; Humans; Insulin; Insulin Resistance; Leptin; Mineralocorticoid Receptor Antagonists; Obesity; Pilot Projects; Polycystic Ovary Syndrome | 2010 |
From the Food and Drug Administration.
Topics: Androstenes; Angioplasty, Balloon, Coronary; Contraceptives, Oral; Coronary Artery Bypass; Coronary Disease; Gastric Balloon; Humans; Obesity; Progesterone Congeners; Recurrence; Saphenous Vein; United States; United States Food and Drug Administration; Weight Loss | 2001 |